nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.03.2017 | Original Article – Clinical Oncology

Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours

verfasst von: Davide Franceschini, Luca Cozzi, Fiorenza De Rose, Piera Navarria, Ciro Franzese, Tiziana Comito, Cristina Iftode, Angelo Tozzi, Lucia Di Brina, Anna Maria Ascolese, Elena Clerici, Giuseppe D’Agostino, Antonella Fogliata, Marta Scorsetti

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

A retrospective analysis was performed on patients treated for lung oligo-metastatic disease from radio-resistant histology groups.

Methods

The primary end point was local control (LC), secondary end points were overall survival (OS) and progression free survival (PFS). Toxicity was scored according to CTCAE 4.03.

Results

200 patients were analyzed: 49.5% of the cases derived from colorectal primary tumors, 20.5% from sarcomas, 12.0% from renal cell carcinoma and the rest from other mixed origin. The mean follow-up was 24.2 months. LC at 1 and 2 years was 91, 84.9%. Primary histology and the presence of extra-pulmonary disease had a significant impact on LC. OS at 1 and 2 years was 88.7, 65.4%. Primary histology, disease free interval, presence of extra-pulmonary disease, number of irradiated lung lesions and age showed a correlation with prognosis at univariate analysis. PFS at 1 and 2 years was 84, 57.7%. The presence of extra-pulmonary disease and the number of irradiated lung lesions correlated with prognosis. Treatment was well tolerated with no G3–4 acute or late toxicity recorded.

Conclusion

Colorectal metastases showed a higher rate of local relapse. However, the factors mostly influencing prognosis were the presence of extra-pulmonary disease and the number of lung lesions.

Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF (2015) Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys 92(4):837–842CrossRefPubMedPubMedCentral

Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95(5):1399–1404CrossRefPubMed

Aloia TA, Vauthey JN, Loyer EM et al (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466 (discussion: 466–467) CrossRefPubMed

Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, Loo BW Jr, Shultz DB, Diehn M (2015 ) Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 92(5):1044–1052CrossRefPubMed

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG (2009) Neuro-cognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain irradiation: a randomized controlled trial. Lancet Oncol 10:1037–1044CrossRefPubMed

Clarke JW, Register S, McGregor JM, Grecula JC, Mayr NA, Wang JZ et al (2010) Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol 33:70–74CrossRefPubMed

De Giacomo T, Rendina EA, Venuta F, Ciccone AM, Coloni GF (1999) Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest 115:1441–1443CrossRefPubMed

Eschrich SA, Pramana J, Zhang H et al (2009) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75:489–496CrossRefPubMedPubMedCentral

Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946CrossRefPubMed

Hellman S, Weichselbaum RR. (1995) Oligometastases. J Clin Oncol 13:8–10CrossRefPubMed

Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed

Hyool K, Tae-Young J, In-Young K, Shin J, Kyung-Sub M, Seung-Jin P (2013) The usefulness of stereotactic radiosurgery for radioresistant brain metastases. J Korean Neurosurg Soc 54:107–111CrossRef

Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed

Lo SS, Teh BS, Mayr NA et al (2010) Stereotactic body radiation therapy for oligometastases. Discov Med 10:247–254PubMed

McCammon R, Schefter TE, Gaspar LE et al (2009) Observation of a dose control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 73:112–118CrossRefPubMed

Milano MT, Katz AW, Zhang H et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886CrossRefPubMed

Okunieff P, Petersen AL, Philip A et al (2006) Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 45:808–817CrossRefPubMed

Pastorino U, Buyse M, Friedel G et al (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The international registry of lung metastases. J Thorac Cardiovasc Surg 113:37–49CrossRefPubMed

Powell JW, Chung CT, Hemangini SR, Canute GW, Hodge CJ, Bassano DA (2008) Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg 109(Suppl):122–128PubMed

Salama JK, Chmura SJ, Mehta N et al (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14:5255–5259CrossRefPubMed

Salama JK, Hasselle MD, Chmura SJ et al (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118:2962–2970CrossRefPubMed

Shiono S, Ishii G, Nagai K et al (2005) Predictive factors for local recurrence of resected colorectal lung metastases. Ann Thorac Surg 80:1040–1045CrossRefPubMed

Shultz DB, Filippi AR, Thariat J et al (2014) Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 9:1426–1433CrossRefPubMed

Sin AH, Cardens RJ, Vannemreddy P, Nanda A (2009) Gamma knife stereotactic radiosurgery for intracranial metastases from conventionally radioresistant primary cancers: outcome analysis of survival and control of brain disease. South Med J 102:41–44CrossRef

Takeda A, Kunieda E, Ohashi T et al (2011) Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 101:255–259CrossRefPubMed

The International Registry of Lung Metastases (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113:37–49CrossRef

Timmerman RD, Park C, Kavanagh BD (2007) The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2:S101–S112CrossRefPubMed

Timmerman RD, Bizekis CS, Pass HI et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59:145–170CrossRefPubMed

van Laarhoven HW, Kaanders JH, Lok J et al (2006) Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 64:473–482CrossRefPubMed

Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G (2007) Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg 84:203–210CrossRefPubMed

Yaeh A, Nanda T, Jani A, Rozenblat T, Qureshi Y, Saad S, Lesser J, Lassman AB, Isaacson SR, Sisti MB, Bruce JN, McKhann GM 2nd, Wang TJ (2015) Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neurooncol 124(3):507–514CrossRefPubMed

Titel: Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours
verfasst von: Davide Franceschini
Luca Cozzi
Fiorenza De Rose
Piera Navarria
Ciro Franzese
Tiziana Comito
Cristina Iftode
Angelo Tozzi
Lucia Di Brina
Anna Maria Ascolese
Elena Clerici
Giuseppe D’Agostino
Antonella Fogliata
Marta Scorsetti
Publikationsdatum: 03.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2373-y

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours